Key clinical point: Among patients with acute myeloid leukemia (AML) with CBFB-MYH11 who underwent allogeneic or autologous hematopoietic stem cell transplantation (HSCT) in remission, D816V KIT mutation, and peri-transplant CBFB-MYH11 measurable residual disease (MRD) monitoring were associated with posttransplant relapse and survival.
Major finding: Patients with D816V KIT mutation had an increased cumulative incidence of relapse (CIR; P less than .001) and worse disease-free survival ( P = .002) vs patients with other or no KIT mutations. The presence of MRD defined by 2.0 log reduction before and 3 months post-HSCT were associated with increased CIR and poorer overall survival (all P less than .001).
Study details : Findings are from a retrospective analysis of 88 patients with AML with CBFB-MYH11 who underwent HSCT in the first (n=81) or second (n=7) complete remission.
Disclosures: This study was supported by the National Research Foundation of Korea, funded by the Ministry of Education and the National R&D Program for Cancer Control, Ministry for Health and Welfare, Republic of Korea. The authors declared no conflicts of interest.
Source: Cho BS et al. Bone Marrow Transplant. 2021 Jun 28. doi: 10.1038/s41409-021-01384-w .